Portions of this exhibit have been omitted for confidential treatment pursuant to Item 601(b)(10)(iv) of Regulation S-K. COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN UNIQURE BIOPHARMA BV AND CSL BEHRING LLC Dated June 24, 2020Commercialization and License Agreement • July 30th, 2020 • uniQure N.V. • Pharmaceutical preparations • New York
This COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is made as of June 24, 2020 (the “Execution Date”) by and between uniQure biopharma BV, a corporation organized under the laws of the Netherlands, having its principal place of business at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands (“uniQure”), and CSL Behring LLC, a limited liability company organized and existing under the laws of Delaware, having a registered office located at 1020 First Avenue, King of Prussia, PA 19406, United States (“Partner”). uniQure and Partner are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
